A new trend in the treatment of type 2 diabetes mellitus with the use of sodium-dependent glucose transporter-2 inhibitors
https://doi.org/10.14341/probl201460447-51
Abstract
Insulin is traditionally the main application point on which all methods for the management of type 2 diabetes mellitus are targeted. One of the new strategies for the treatment of this pathology utilizes sodium-dependent glucose transporter-2 (SGLT-2) inhibitors transforms this approach making kidneys the new point of application of antidiabetic therapy. SGLT-2 functions as a tunnel built into the epithelial wall of the initial segment of the proximal tubules in the nephron. When the channel is open, glucose is filtered into primary urine and can be reabsorbed in the proximal tubule. Based on this observation, the pharmaceutical companies began to search for the chemical substances that could be used to close the SGLT-2 tunnels and thereby interfere with the reverse flow of glucose from urine to blood, i.e. stimulate glycosuria. During the last decade, a few alternative molecules have been synthesized capable of selective inhibition of SGLT-2. At present, two of them, dapagliflozin and canagliflozin, are approved for the clinical application.
About the Authors
V G Kadzharyan
Zaporozhye State Medical University, Zaporozhye
Russian Federation
Russian Federation
N I Kapshitar’
Zaporozhye State Medical University, Zaporozhye
Russian Federation
Russian Federation
References
1. Противодиабетический препарат Форксига (дапаглифлозин) возможно будет одобрен в Европе [Электронный ресурс]. // Клиническая фармация. 2013. [Antidiabetic drug Forxiga (dapagliflozin) can be approve in Europe. Klinicheskaya farmatsiya. 2013] Available from: http://clinical-pharmacy.ru/digest/new-lekarstva/241-protivodiabeticheskiy-preparat-forksiga-dapagliflozin-odobren-v-evrope.html
2. Тронько Н.Д., Маньковский Б.Н. Государственная программа «Сахарный диабет». // Лікування та діагностика. 2009;(1):58-59. [Tron'ko ND, Man'kovskiy BN. Gosudarstvennaya programma «Sakharnyy diabet». Lіkuvannya ta dіagnostika. 2009;(1):58-59]
3. WHO. Fact sheet N°312. January 2011. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/print.html
4. Пресс-служба «Еженедельника АПТЕКА». Сахарный диабет: чем лечить сегодня и завтра [Электронный ресурс]. // Еженедельник аптека. 2013;874(3). [Press-service of "Weekly PHARMACY." Diabetes mellitus: the treat today and tomorrow [electronic resource]. "Weekly pharmacy." 2013;874(3).] Available from: http://www.apteka.ua/article/177759
5. Gardner A. Drug Helps Tackle Type 2 Diabetes in New Way, Study Says. HealthDay 24 June 2010. Available from: http://consumer.healthday.com/diabetes-information-10/misc-diabetes-news-181/drug-helps-tackle-type-2-diabetes-in-new-way-study-says-640519.html
6. NICE says yes to dapagliflozin for some people with type 2 diabetes in final draft guidance. NICE. 29 May 2013. Available from: http://www.nice.org.uk/News/Press-and-Media/nice-says-yes-to-dapagliflozin-for-some-people-with-type-2-diabetes-in-final-draft-guidance
7. Gebel E. New SGLT-2 Meds Target the Kidneys. Diabetes Forecast. 2013;(6):207-212. Available from: http://www.diabetesforecast.org/2013/jun/new-sglt-2-meds-target-the-kidneys.html?loc=morefrom
8. Шварц В.Я. Новый принцип лечения сахарного диабета 2-го типа путем стимуляции глюкозурии. // Проблемы эндокринологии. 2012;58(4):54–57. [Shvarts V. A new principle of the treatment of type 2 diabetes mellitus by stimulation of glucosuria. Problemy Endokrinologii. 2012;58(4):54-57.] doi: 10.14341/probl201258454-57
9. Mike H. SGLT-2 Drugs = A New Class of Medication, Since Diabetes Is Like a River. Diabetes Mine. 2 July 2012. Available from: http://www.diabetesmine.com/2012/07/sglt-2-drugs-a-new-class-of-medication-since-diabetes-is-like-a-river.html
10. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. Journal of Clinical Investigation. 2002;110(6):851-860. doi: 10.1172/jci200215318
11. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - A randomized placebo-controlled trial. American Heart Journal. 2013;166(2):217-223.e211. doi: 10.1016/j.ahj.2013.05.007
12. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, et al. Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects. Clinical Pharmacology & Therapeutics. 2009;85(5):520-526. doi: 10.1038/clpt.2008.251
13. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, et al. Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-2022. doi: 10.2337/dc11-0606
14. Шведова А.Е. Дапаглифлозин: новый многообещающий препарат для лечения диабета не смог получить одобрение FDA. Diabetology.ru. 2011. (электронный ресурс) [Shvedova AE. Dapagliflozin: a promising new drug for treatment of diabetes could not get the approval by FDA. Diabetology.ru. 2011.] Available from: http://diabetology.ru/forspecialist/specnews/specialistnews/409-dapagliflozin-novyj-mnogoobeshhayushhij-preparat-dlya-lecheniya-diabeta-ne-smog-poluchit-odobrenie-fda.html
15. Naseem S. Miller. Newcomer canagliflozin improves beta-cell function in type 2 diabetes. Internal Medicine News Digital Network. 2013.
16. Препарат дапаглифлозин отклонен FDA. Ассоциация превентивной и антиейджинг медицины (электронный ресурс). [Preparat dapagliflozin otklonen FDA. Assotsiatsiya preventivnoy i antieydzhing meditsiny.] Available from: http://apam.org.ua/index.php?option=com_content&view=article&id=146:-fda&catid=1:aa-news&Itemid=55
17. Burki TK. FDA rejects novel diabetes drug over safety fears. The Lancet. 2012;379(9815):507. doi: 10.1016/s0140-6736(12)60216-5
18. Nainggolan L. FDA Approvals: First-in-Class Diabetes Drug for Adults. CME Author: Laurie Barclay. Medscape Education. 2013.
19. Endocrinologic and Metabolic Drugs Advisory Committee. Canagliflozin as an Adjunctive Treatment to Diet and Exercise Alone or Co-administered with Other Antihyperglycemic Agents to Improve Glycemic Control in Adults with Type 2 Diabetes Mellitus. Janssen Research & Development. Advisory committee briefing materials. 2012.
20. Morgan Liscinsky. FDA approves Invokana to treat type 2 diabetes. FDA NEWS RELEASE. 2013.
21. Терещенко А. Новости конгресса американской диабетической ассоциации АДА 2012. // Здоров’я України. 2012;(15-16):292-293. [Tereshchenko A. Novosti kongressa amerikanskoy diabeticheskoy assotsiatsii ADA 2012. Zdorov’ya Ukraїni. 2012;(15-16):292-293.]
22. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism. 2011;13(10):928-938. doi: 10.1111/j.1463-1326.2011.01434.x
Review
For citations:
Kadzharyan V.G., Kapshitar’ N.I. A new trend in the treatment of type 2 diabetes mellitus with the use of sodium-dependent glucose transporter-2 inhibitors. Problems of Endocrinology. 2014;60(4):60-64. (In Russ.) https://doi.org/10.14341/probl201460447-51
Views:
548
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
